Table 1.

Patient data

Source of Sample
University of MichiganSt. Louis UniversityCalifornia Pacific Medical Center
Healthy (n = 20)Cirrhosisa (n = 20)HCCa (n = 20)HCV infected (n = 43)Cirrhosisa (n = 32)HCCa (n = 76)Liver disease (n = 50)HCCa (n = 10)
Etiology (HBV/HCV/crypto/alcohol/other)b, %N/A5/48/20/18/911/51/24/10/4N/AN/A14/52/6/20/820/60/20/0/030/20/40/10/0
Age (mean ± SD), y54 ± 358 ± 358.6 ± 1255 ± 850 ± 858.04 ± 1151 ± 1358 ± 8
Gender (M:F), %50:5060:4075:2550:5084:1671:2956:4490:10
MELD scoreN/A9 ± 210.3 ± 4N/AN/A11.8 ± 5NANA
Child class (A/B/C)c, %N/A40/54/6/048/42/10/0N/A88/8/452/29/9/10NANA
Tumor stage (1/2/3/4)d, %N/AN/A21/40/26/13N/ANA26/48/12/14NA100/0/0/0

Abbreviations: MELD, model for end-stage liver disease; N/A, not available.

aHCC or cirrhosis was determined by MRI or by liver biopsy.

bcrypto, cryptogenic liver disease; alcohol, alcohol-induced liver disease; other, liver disease of unknown origin.

cThe percent of patients with each Child–Pugh score is given as a percentage in each group.

dTumor staging was determined by using the United Network of Organ Sharing–modified TNM staging system for HCC. The percent of patients within each stage is given.